Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Settings
Settings
Dynamic quotes
OFFON

school135perm Homepage > Equities > Xetra > STADA Arzneimittel SAZ DE0007251803

STADA ARZNEIMITTEL (SAZ)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions
Quotes 5-day view Delayed Quote. Delayed Xetra
01/09/2018 01/10/2018 01/11/2018 01/12/2018 01/15/2018 Date
89.26(c) 88.66(c) 88.66(c) 88.58(c) 88.04 Last
24 269 25 248 29 454 37 896 18 782 Volume
+0.70% -0.67% 0.00% -0.09% -0.61% Change
More quotes
Financials (€)
Sales 2017 2 291 M
EBIT 2017 320 M
Net income 2017 160 M
Debt 2017 1 160 M
Yield 2017 0,95%
Sales 2018 2 415 M
EBIT 2018 337 M
Net income 2018 197 M
Debt 2018 1 037 M
Yield 2018 1,06%
P/E ratio 2017 33,56
P/E ratio 2018 26,90
EV / Sales2017 2,92x
EV / Sales2018 2,72x
Capitalization 5 522 M
More Financials
Company
STADA Arzneimittel AG engages in the provision of healthcare and pharmaceutical products.It operates through the Generics and Branded Products segments.The Generics segment produces and distributes generic drugs.The Branded Products segment sells branded healthcare products and medicines.The...
Sector
Pharmaceuticals
Calendar
02/02 | 10:00amShareholder meeting
More about the company
Surperformance© ratings of STADA Arzneimittel
Trading Rating : Investor Rating :
More Ratings
Latest news on STADA ARZNEIMITTEL
03:15pSTADA ARZNEIMITTEL AG : Release according to Article 40, Section 1 of the WpHG [..
01/12STADA ARZNEIMITTEL AG : Release according to Article 40, Section 1 of the WpHG [..
01/10Nestle frontrunner for Merck KGaA's consumer health business - Bloomberg
2017STADA : domination and profit and loss transfer agreement pursuant to sections 2..
2017STADA ARZNEIMITTEL AG : 19 December 2017, 17.15 hours; STADA: domination and pro..
2017Germany's Merck in fresh bid to enter U.S. MS pill market
2017Perrigo lines up bid for Merck's consumer health unit - sources
2017Paul Singer's Elliott takes stake in takeover target Uniper
2017Nestle, Stada prepare rival bids for Germany's Merck consumer health - source..
2017STADA HEALTH REPORT 2017 : Young adults lack health education
More news
Sector news : Generic Pharmaceuticals
01/12Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
01/12ASTRAZENECA : Receives FDA Approval for Breast Cancer Treatment
01/12WPP Buys London-based Mash Strategy
01/12TEVA PHARMACEUTICAL INDUSTRIES : Ohio Talks Settlement Of Opioid Lawsuits -- WSJ
More sector news : Generic Pharmaceuticals
school135perm Strategies on STADA ARZNEIMITTEL
STADA ARZNEIMITTEL - 2014
Bearish scenario preferred
SELL
STADA ARZNEIMITTEL - 2014
Into a recovery phase
BUY
More Strategies
Latest Tweets
03:14pSTADA Arzneimittel AG: Release according to Article 40, Section 1 of the WpHG..
01/12STADA Arzneimittel AG: Release according to Article 40, Section 1 of the WpHG..
01/12STADA Arzneimittel AG: Release according to Article 40, Section 1 of the WpHG..
2017STADA Arzneimittel given €74.40 PT by Nord/LB. sell rating.
2017STADA Arzneimittel given €74.40 PT by Nord/LB. sell rating.
More tweets
Qtime:36
News from SeekingAlpha
2017STADA Arzneimittel's (STDAF) CEO Claudio Albrecht on Q3 2016 Results - Earnin..
2017Stada Arzneimittel AG reports Q3 results
2017Stada Arzneimittel AG 2017 Q3 - Results - Earnings Call Slides
2017MERGER OF EQUALS : Linde Shares More Attractive Relative To Praxair
2017Second-Quarter Deals Show A Sector Set On Pause
Chart STADA ARZNEIMITTEL
Duration : Period :
STADA Arzneimittel Technical Analysis Chart | SAZ | DE0007251803 | school135perm
Technical analysis trends STADA ARZNEIMITTEL
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 11
Average target price 66,8 €
Spread / Average Target -25%
EPS Revisions
Managers
NameTitle
Claudio Albrecht Chairman-Executive Board
Günter von Au Chairman-Supervisory Board
Mark Burgess Keatley Chief Financial Officer
Barthold Piening Chief Technical Officer
Halil Duru Member-Supervisory Board
Sector and Competitors
Copyright © 2018 Surperformance. All rights reserved.